PL363431A1 - The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders - Google Patents

The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Info

Publication number: PL363431A1
Authority: PL; Poland
Prior art keywords: copolymer; treatment; nervous system; central nervous; system disorders
Prior art date: 2000-06-05

Application number

PL01363431A

Other languages

Polish (pl)

Inventor

Wee V. Yong

Sophie Chabot

Original Assignee

Teva Pharmaceuticals Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-05

Filing date

2001-06-05

Publication date

2004-11-15

2001-06-05 Application filed by Teva Pharmaceuticals Industries, Ltd. filed Critical Teva Pharmaceuticals Industries, Ltd.

2004-11-15 Publication of PL363431A1 publication Critical patent/PL363431A1/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL01363431A 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders PL363431A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58752300A	2000-06-05	2000-06-05
PCT/US2001/018248 WO2001093828A1 (en)	2000-06-05	2001-06-05	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Publications (1)

Publication Number	Publication Date
PL363431A1 true PL363431A1 (en)	2004-11-15

Family

ID=24350145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01363431A PL363431A1 (en)	2000-06-05	2001-06-05	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Country Status (9)

Country	Link
EP (1)	EP1292279A4 (en)
JP (1)	JP2003535118A (en)
AU (2)	AU7528001A (en)
CA (1)	CA2411536A1 (en)
HU (1)	HUP0302333A3 (en)
IL (1)	IL153236A0 (en)
PL (1)	PL363431A1 (en)
WO (1)	WO2001093828A1 (en)
ZA (1)	ZA200210084B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1098902A4 (en)	1998-07-23	2002-07-24	Yeda Res & Dev	Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (en)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Treatment of Crohn's disease with copolymer 1 and polypeptides
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en)	2000-02-18	2003-08-13	Yeda Res & Dev	Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL162127A0 (en)	2001-12-04	2005-11-20	Teva Pharma	Process for the measurement of the potency of glatiramer acetate
PL1797109T3 (en)	2004-09-09	2016-11-30		Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
PL2949335T3 (en)	2009-08-20	2017-07-31	Yeda Research & Development Company, Ltd.	Low frequency glatiramer acetate therapy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
BR112013008573A2 (en)	2010-10-11	2016-07-12	Teva Pharma	biomarker cytokines as indicators of clinical response to glatiramer acetate.
AU2012323345A1 (en)	2011-10-10	2014-05-22	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
US9617596B2 (en)	2012-10-10	2017-04-11	Teva Pharmaceutical Industries, Ltd.	Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (en)	2013-10-21	2015-05-29	Teva Pharma	GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
DK3185882T3 (en)	2014-08-29	2020-01-27	Region Midtjylland	Positively charged copolymers for use as antimicrobial agents
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
CN106924175B (en) *	2015-12-29	2020-07-03	深圳翰宇药业股份有限公司	Pharmaceutical composition for treating multiple sclerosis
US11058720B2 (en)	2016-05-20	2021-07-13	Cedars-Sinai Medical Center	Methods of treating or preventing alzheimer's disease and associated conditions
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
MX2019010174A (en)	2017-03-26	2019-10-15	Mapi Pharma Ltd	Glatiramer depot systems for treating progressive forms of multiple sclerosis.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5800808A (en) *	1994-05-24	1998-09-01	Veda Research And Development Co., Ltd.	Copolymer-1 improvements in compositions of copolymers
GB9411292D0 (en) *	1994-06-06	1994-07-27	Teva Pharma	Pharmaceuticals compositions
US5665764A (en) *	1995-06-02	1997-09-09	Warner-Lambert Company	Tricyclic inhibitors of matrix metalloproteinases
IL119989A0 (en) *	1997-01-10	1997-04-15	Yeda Res & Dev	Pharmaceutical compositions for oral treatment of multiple sclerosis
PT1248643E (en) *	2000-01-20	2005-10-31	Yeda Res & Dev	USEFULNESS OF COPOLYMER 1 AND CONGENERAL AND T-CELLED PEOPLE AND POLYMPEPTIDES TREATED WITH THESE COMPOUNDS FOR NEUROPROTECTING THERAPY
US20020037848A1 (en) *	2000-06-07	2002-03-28	Michal Eisenbach-Schwartz	Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

2001
- 2001-06-05 AU AU7528001A patent/AU7528001A/en active Pending
- 2001-06-05 AU AU2001275280A patent/AU2001275280B2/en not_active Ceased
- 2001-06-05 HU HU0302333A patent/HUP0302333A3/en unknown
- 2001-06-05 WO PCT/US2001/018248 patent/WO2001093828A1/en not_active Application Discontinuation
- 2001-06-05 EP EP01941973A patent/EP1292279A4/en not_active Withdrawn
- 2001-06-05 CA CA002411536A patent/CA2411536A1/en not_active Abandoned
- 2001-06-05 IL IL15323601A patent/IL153236A0/en unknown
- 2001-06-05 JP JP2002501401A patent/JP2003535118A/en active Pending
- 2001-06-05 PL PL01363431A patent/PL363431A1/en not_active Application Discontinuation
2002
- 2002-12-12 ZA ZA200210084A patent/ZA200210084B/en unknown

Also Published As

Publication number	Publication date
HUP0302333A3 (en)	2005-07-28
AU7528001A (en)	2001-12-17
ZA200210084B (en)	2003-12-12
CA2411536A1 (en)	2001-12-13
EP1292279A1 (en)	2003-03-19
EP1292279A4 (en)	2005-01-12
AU2001275280B2 (en)	2006-03-16
IL153236A0 (en)	2003-07-06
JP2003535118A (en)	2003-11-25
HUP0302333A2 (en)	2003-11-28
WO2001093828A1 (en)	2001-12-13

Similar Documents

Publication	Publication Date	Title
IL153236A0 (en)	2003-07-06	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0100069A3 (en)	2002-04-29	4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0004439A3 (en)	2001-12-28	1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
HK1046274A1 (en)	2003-01-03	Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
AU9112201A (en)	2002-04-02	Pulmonary delivery in treating disorders of the central nervous system
HUP0100786A3 (en)	2002-12-28	Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
IL151946A0 (en)	2003-04-10	2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0401023A3 (en)	2004-10-28	Use of flibanserin in the treatment of sexual disorders
MXPA02004770A (en)	2003-10-14	Therapeutic compositions and methods of use thereof.
EP0924983A4 (en)	1999-08-25	S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU2001266152A1 (en)	2002-01-02	Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
IL155589A0 (en)	2003-11-23	Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
ZA97741B (en)	1997-07-30	Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2001256855A1 (en)	2001-11-20	Preparation for the prevention and treatment of ocular disorders
HUP0204050A3 (en)	2004-09-28	Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
IL160018A0 (en)	2004-06-20	Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
EP1079764A4 (en)	2001-09-12	The treatment of sexual dysfunction in certain patient groups
GB0015228D0 (en)	2000-08-16	Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
HUP0301553A3 (en)	2005-05-30	Pharmaceutical compositions and their use for treating neurological disorders
AU2002226060A1 (en)	2002-06-18	Compositions containing gangliosides for use in the treatment of skin disorders
IL129460A0 (en)	2000-02-29	Use of lofexidine in the treatment of behavioral disorders
AU5963396A (en)	1996-12-30	Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
AU2002210763A1 (en)	2002-05-15	Use of 1-ebio in the treatment of bipolar disorders
AU6330300A (en)	2001-01-30	Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
AU2001292500A1 (en)	2002-04-08	1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain

Legal Events

Date	Code	Title	Description
2009-09-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)